



Gossamer Bio to Present at Upcoming Investor Conferences

August 29, 2025

SAN DIEGO--(BUSINESS WIRE)--Aug. 29, 2025-- [Gossamer Bio, Inc.](#) (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of serralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the following investor conferences in September.

Cantor Global Healthcare Conference

Date / Time: September 3rd, at 9:10 AM ET
Format: Fireside Chat & 1x1's
Location: New York, NY
Webcast Link: <https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=93028624&checkCompany=1&checkEmail=1&checkName=1>

Wells Fargo Healthcare Conference

Date / Time: September 4th
Format: 1x1's
Location: Boston, MA

H.C. Wainwright 27th Annual Global Healthcare

Date / Time: September 9th, at 8:00 AM ET
Format: Fireside Chat & 1x1's
Location: New York, NY

About Gossamer Bio

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of serralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250829692001/en/): <https://www.businesswire.com/news/home/20250829692001/en/>

For Investors and Media

Bryan Giraud, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com

Source: Gossamer Bio, Inc.